Status:
COMPLETED
Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride
Lead Sponsor:
Sanofi
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
35-70 years
Phase:
PHASE4
Brief Summary
Analyse the glucose profile, based on continuous glucose monitoring by CGMS, in type 2 diabetics inadequately controlled by metformin, before and after the addition of Glimepiride.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men or women aged 35 to 70 years
- Having given their consent
- Type 2 diabetics (HBA1c greater than 6.5%
- Fasting glycaemia greater than 1.40 g/l) not controlled by Metformin for at least 6 weeks.
Exclusion
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2003
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00633425
Start Date
October 1 2002
End Date
October 1 2003
Last Update
March 28 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Paris, France